FGF23 induces left ventricular hypertrophy

作者：Faul Christian; Amaral Ansel P; Oskouei Behzad; Hu Ming Chang; Sloan Alexis; Isakova Tamara; Gutierrez Orlando M; Aguillon Prada Robier; Lincoln Joy; Hare Joshua M; Mundel Peter; Morales Azorides; Scialla Julia; Fischer Michael; Soliman Elsayed Z; Chen Jing; Go Alan S; Rosas Sylvia E; Nessel Lisa; Townsend Raymond R; Feldman Harold I; Sutton Martin St John; Ojo Akinlolu; Gadegbeku Crystal; Di Marco Giovana Seno; Reuter Stefan; Kentrup Dominik; Tiemann Klaus

来源：Journal of Clinical Investigation, 2011, 121(11): 4393-4408.

DOI：10.1172/JCI46122

Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor-dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intrarnyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF-receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.

• 出版日期2011-11